Login
Navigate Fool.com
Will OSIR beat
the market?
Community Rating: 1 Star: Ominous

12.39 -0.41 (-3.20%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.75
Previous Close $12.80
Daily Range $12.33 - $13.03
52-Week Range $10.00 - $27.40
Market Cap $424.0M
P/E Ratio -309.75
Dividend (Yield) $0.00 (0.0%)
Volume 272,435
Average Daily Volume 276,410
Current FY EPS -$0.25

How do you think OSIR
will perform against the market?

Top OSIR Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted September 23, 2011

I scored on a couple of hold-my-nose green thumbs on Osiris last year so I thought I might give it a shot again as I drive for score leadership. Of course, the same strategy could put me in the cellar … More

0 Replies Reply Report this Post
 

Aarin7 (< 20)
Submitted July 31, 2008

At $16, this stock is over priced. It has a lot of future potential but has very little profits to speak of. Their trials in adult stem research have shown major break troughs but are expensive. Thi … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

3 Ways 3-D Bioprinting Can Disrupt the Health-Care Industry

Will 3-D bioprinting technology from companies such as Organovo disrupt older technologies from Boston Scientific, Osiris Therapeutics, and Hanger?

Why Osiris Therapeutics Inc. Shares Tanked

Shareholders react negatively to the departure of an important piece of the Osiris Therapeutics puzzle.

3 Biggest Biotech Winners Last Week

3 health care stocks that were on the rise last week: Idenix Pharmaceuticals Inc (Nasdaq: IDIX), Osiris Therapeutics, Inc. (Nasdaq: OSIR), and Dyax Corp. (Nasdaq: DYAX).

3 Humongous Health-Care Stocks This Week

Which health-care stocks raked in the most treats for investors this Halloween week? Dyax, Idenix, and Osiris delivered the goodies big-time.

Why Osiris Therapeutics Inc. Shares Spiked Higher

Osiris reports its third-quarter results, and investors like what they see. Is this the time to jump on board or has this train long left the station?

This Week in Biotech

A surprise FDA approval, positive early-stage pancreatic cancer trial results, and a unanimous FDA panel recommendation for what could be a $7 billion drug are among this week's top biotech stories.

This Biotech Trifecta Could Revolutionize Cancer

A new partnership between Intrexon, Mesoblast, and Ziopharm aims to develop a new class of novel cancer therapeutics.

Why This Acquisition Makes Sense

Mesoblast's acquisition of Osiris Therapeutics' MSC business makes strategic sense.

Mid-Afternoon Market Update: JC Penney Falls on Massive Volume Following Imperial Capital Price Targ

Mid-Afternoon Market Update: JC Penney Falls on Massive Volume Following Imperial Capital Price Target

Why Osiris Therapeutics Inc. Shares Were Hammered

Osiris' shareholders are going to have to wait a bit longer before its lead drug has the potential to bring in the big bucks!

See More OSIR News...

Sector

Healthcare

Industry

Drugs

Osiris Therapeutics, Inc. (OSIR) Description

A stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Website: http://www.osiristx.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks